US FDA Reopens Door For CBD Safety Data, But NPA Says Window Closing For Setting Safe Level
As it recently told Congress it would, FDA reopens docket on “Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived,. "Reopening the comment period will do nothing to protect public health when the FDA is already sitting on a ticking time bomb," says NPA head Daniel Fabricant.
The US Food and Drug Administration’s latest step in considering allowing lawful use of hemp-derived cannabidiol in non-drug products – accepting additional comments – isn’t a step in the right direction, says the Natural Products Association.
The agency on 10 March published a Federal Register notice to do as it recently told members of Congress...